Target Price | $48.93 |
Price | $4.06 |
Potential |
1,105.14%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Karyopharm Therapeutics, Inc. 2026 .
The average Karyopharm Therapeutics, Inc. target price is $48.93.
This is
1,105.14%
register free of charge
$75.00
1,747.29%
register free of charge
$15.00
269.46%
register free of charge
|
|
A rating was issued by 7 analysts: 6 Analysts recommend Karyopharm Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Karyopharm Therapeutics, Inc. stock has an average upside potential 2026 of
1,105.14%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 145.24 | 149.62 |
0.54% | 3.01% | |
Net Margin | -54.49% | -80.62% |
49.65% | 47.96% |
6 Analysts have issued a sales forecast Karyopharm Therapeutics, Inc. 2025 . The average Karyopharm Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Karyopharm Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Karyopharm Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -9.41 | -14.34 |
49.92% | 52.39% | |
P/E | negative | |
EV/Sales | 0.77 |
6 Analysts have issued a Karyopharm Therapeutics, Inc. forecast for earnings per share. The average Karyopharm Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Karyopharm Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Feb 10 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 15 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
Analyst Rating | Date |
---|---|
Locked
Baird:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 26 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 10 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 15 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 06 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.